T2 Biosystems Announces Positive Results upon Completion of U.S. Clinical Evaluation for the T2Biothreat Panel
T2 Biosystems announced positive results for the T2Biothreat™ Panel after completing U.S. clinical evaluations. The panel, designed for direct-from-blood testing, demonstrates high sensitivity and specificity in detecting six biothreat pathogens including those causing anthrax and plague. The company aims to file for FDA clearance and then pursue commercial sales. Rapid detection of these pathogens can significantly improve clinical outcomes and reduce mortality rates, with infections having fatality rates of 40-90%. Testing involved over 470 negative samples and 350 positive samples, showing impressive performance metrics.
- High sensitivity and specificity demonstrated for T2Biothreat Panel in clinical evaluation.
- Rapid detection (within 4 hours) of critical biothreat pathogens can improve treatment outcomes.
- Plans to file for FDA clearance could lead to commercial sales and revenue growth.
- None.
Results demonstrated very high sensitivity and specificity across all six biothreat targets exceeding target performance requirements
LEXINGTON, Mass., Feb. 13, 2023 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced positive results upon completion of the U.S. clinical evaluation for the T2Biothreat™ Panel.
"We believe the T2Biothreat Panel demonstrates very high sensitivity and specificity for a direct-from-blood multi-target biothreat product and is the only such product developed by a U.S. owned company,” stated John Sperzel, Chairman and CEO of T2 Biosystems. “We are extremely pleased with the results of the clinical evaluation. We have now shifted our attention to filing the submission with FDA for U.S. regulatory clearance and subsequently pursuing commercial sales, with the goal of protecting Americans from the threat of deliberate or naturally occurring outbreaks of biothreat pathogens.”
The T2Biothreat Panel is a fully-automated, direct-from-blood test designed to run on the T2Dx® Instrument and simultaneously detects six biothreat pathogens identified as threats by the U.S. Centers for Disease Control and Prevention, including the organisms that cause anthrax (Bacillus anthracis), tularemia (Francisella tularensis), glanders (Burkholderia mallei), melioidosis (Burkholderia pseudomallei), plague (Yersinia pestis), and typhus (Rickettsia prowazekii). Rapid detection of these pathogens is essential to getting infected patients on the appropriate antimicrobial therapy and improving clinical outcomes.
In the event of a public health emergency involving biothreat pathogens, rapid and accurate diagnostic testing is expected to play a central role in minimizing health and economic impact. If not treated promptly, infections with these pathogens can result in mortality rates of 40
The clinical evaluation was designed to support a U.S. Food and Drug Administration (FDA) submission and included testing of the T2Biothreat Panel at MRIGlobal, a Biosafety Level 3 laboratory specializing in working with biothreat pathogens, and Oschner Medical Center. Testing included over 470 negative blood samples from both healthy and febrile subjects and 350 contrived positive samples. The results of the clinical trial demonstrated very high sensitivity and specificity across all six targets.
This project has been funded in whole or in part with federal funds from the U.S. Department of Health and Human Services, Administration for Strategic Preparedness and Response, Biomedical Advanced Research and Development Authority (BARDA), under contract number 75A50119C00053.
About T2 Biosystems
T2 Biosystems, a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, is dedicated to improving patient care and reducing the cost of care by helping clinicians effectively treat patients faster than ever before. T2 Biosystems’ products include the T2Dx® Instrument, the T2Bacteria® Panel, the T2Candida® Panel, the T2Resistance® Panel, and the T2SARS-CoV-2™ Panel and are powered by the proprietary T2 Magnetic Resonance (T2MR®) technology. T2 Biosystems has an active pipeline of future products, including the T2Biothreat™ Panel, the T2Cauris™ Panel, and T2Lyme™ Panel, as well as next-generation products for the detection of bacterial and fungal pathogens and associated antimicrobial resistance markers. For more information, please visit www.t2biosystems.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, without limitation, statements regarding the ability of the T2Biothreat Panel to simultaneously detect six biothreat pathogens, timing of filing of an FDA submission, product demand, and the ability of the T2Biothreat Panel to protect Americans from the threat of deliberate or naturally occurring outbreaks of biothreat pathogens, as well as statements that include the words “expect,” “may,” “should,” “anticipate,” and similar statements of a future or forward-looking nature. These forward-looking statements are based on management’s current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, (i) any inability to (a) realize anticipated benefits from commitments, contracts or products; (b) successfully execute strategic priorities; (c) bring products to market; (d) expand product usage or adoption; (e) obtain customer testimonials; (f) accurately predict growth assumptions; (g) realize anticipated revenues; (h) incur expected levels of operating expenses; or (i) increase the number of high-risk patients at customer facilities; (ii) failure of early data to predict eventual outcomes; (iii) failure to make or obtain anticipated FDA filings or clearances within expected time frames or at all; or (iv) the factors discussed under Item 1A. “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021, filed with the U.S. Securities and Exchange Commission, or SEC, on March 23, 2022, and other filings the Company makes with the SEC from time to time, including our Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. These and other important factors could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management’s estimates as of the date of this press release. While the Company may elect to update such forward-looking statements at some point in the future, unless required by law, it disclaims any obligation to do so, even if subsequent events cause its views to change. Thus, no one should assume that the Company’s silence over time means that actual events are bearing out as expressed or implied in such forward-looking statements. These forward-looking statements should not be relied upon as representing the Company’s views as of any date subsequent to the date of this press release.
Investor Contact:
Philip Trip Taylor, Gilmartin Group
ir@T2Biosystems.com
415-937-5406
FAQ
What are the results of T2 Biosystems' T2Biothreat Panel clinical evaluation?
When does T2 Biosystems plan to submit the T2Biothreat Panel for FDA approval?
What pathogens can the T2Biothreat Panel detect?
How does the T2Biothreat Panel improve patient care?
What is the expected impact of the T2Biothreat Panel in public health emergencies?
